This is consistent with anecdotal reports showing the increase in semaglutide ADM use being larger in some metropolitan cities than others, and does not always correlate with high diabetes prevalence (Trilliant Health, 2023)
It's all labeled for "research use only." Alongside reta, he lists another not-yet-for-sale drug from Novo Nordisk, called cagrilintide, or cagri, and a popular concoction: cagri-reta, blending two in-development GLP-1s from two different drugmakers
While there may be some resistance to the conduction of clinical trials of pharmacological interventions in these clinical populations, the mechanistic profile of GLP-1RAs clearly suggests that these medications may play a role in the treatment of certain specific eating disorders, such as BED
Redox Biol, 2018
First Mover States in GLP-1 Coverage Colorado No state garnered more attention than Colorado
Gradual dose escalation and monitored weight loss form the cornerstone of risk reduction